The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results
Open accessAbstract
Clinical trials of cardiovascular therapeutics have been criticized for underrepresentation of older adults with frailty and multiple chronic conditions. Major strides have been made in the past decade to increase representation of this population, as exemplified by clinical trials of transcatheter aortic valve replacement (TAVR).1,2 While more high-quality evidence is being generated to guide treatment in older adults, the challenge remains to interpret treatment effect in a manner that is informative and intuitive to clinical communities. This is particularly important for older adults with frailty and with limited life expectancy in whom the expected benefit may be too small or remote to justify the risk of treatmentrelated adverse events. Most cardiovascular trials conventionally report treatment effect in terms of relative risk reduction (eg, hazard ratio [HR]) and absolute risk reduction (or equivalently, number needed to treat) for deaths or cardiovascular events at a specific point. In 2010, restricted mean survival time (RMST) was proposed as an alternative measure of treatment effect that offers some advantages in design, analysis, and interpretation over the conventional measures.3-5 In this Viewpoint, we explain how different measures of treatment effect are interpreted for evidence-based communication and their caveats using the 5-year follow-up data from the Placement of Aortic Transcatheter Valves (PARTNER) A and B trials1,2 as an example. The HR compares the hazard (ie, instantaneous rate) of a clinical event in a treatment group with that in a control group. It is usually estimated from a Cox proportional hazards model under the assumption that the hazard in a treatment group remains proportional to the hazard in a control group at any point during the study period (ie, proportional hazards assumption). In the PARTNER B trial1 that compared TAVR with medical treatment, an HR of 0.50 meant that the hazard of death in patients with TAVR was always 50% lower than that in patients receiving medical treatment throughout the 5 years (Table).6 However, in the PARTNER A trial2 that compared TAVR with surgical aortic valve replacement (SAVR), the hazard in the first 30 days was greater in patients with SAVR and then became similar to that in patients with TAVR. In this situation, the ratio of the 2 hazards is not constant, and interpretation of the 5-year HR is unclear. Moreover, the meaning of the HR is not intuitive to clinical communities because HRs cannot be interpreted as risk ratio at each point. When the event rate is very low or the follow-up time is very short, the HR is numerically similar to risk ratio. As a ratio measure by itself, it is difficult to appreciate the magnitude of treatment effect based on the HR without knowing the hazard in the control group. Presenting the HR alone tends to influence patients to accept treatment compared with when they are presented the absolute risk difference.7 The median survival time difference can enhance intuitive interpretation of treatment effect. In the PARTNER B trial, the median survival time for patients with TAVR was 19 months longer than that for medically treated patients (Table).6 Although this interpretation may be intuitive, the median survival time is insensitive to outliers, such as patients who die shortly after TAVR or those who survive a long time. In addition, the estimation procedure for the median survival time difference can be unstable, as evidenced by wide 95% CIs. The 95% CI of the median survival time difference from the PARTNER A trial indicates that the median survival time of patients with TAVR could be 4 months shorter to 13 months longer than that of patients with SAVR, which does not exclude a clinically meaningful difference. Moreover, when the cumulative incidence of the event is less than 50%, the median survival time cannot be estimated from the study. Absolute risk difference is another alternative measure that can be used to improve interpretability of treatment effect.7 Because it is estimated based on cumulative numbers of events at a given time, it is agnostic to whether the events have occurred earlier or later during the study period. This information may be important in some older patients in whom delaying events by a certain amount of time can be meaningful. The number needed to treat is derived from absolute risk difference (Table).6 The estimate from the PARTNER B trial suggests that 5 patients need to be treated with TAVR, rather than medical treatment, to prevent a death in 5 years. Although the number needed to treat may sound intuitive to clinicians, it may be difficult for patients to understand.7 When the absolute risk difference is not statistically significant, as observed in the PARTNER A trial, the number needed to treat cannot be interpreted easily and is therefore often omitted from the published report. Restricted mean survival time is a well-established, yet underused, measure that can be interpreted as the mean event-free survival time up to a prespecified, clinically important point.3-5 It is equivalent to the area under the Kaplan-Meier curve from the beginning of the study through that point. The RMST difference means gain or loss in the event-free survival time owing to treatment vs control during this period. The PARTNER B trial showed that patients with TAVR lived, on average, 13 additional months in 5 years than medically treated patients (Table).6 In the PARTNER A trial, no statistically significant difference was found in the 5-year RMST between TAVR and SAVR. The 95% CI suggests that patients with TAVR may live 3 fewer months VIEWPOINT
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mack, M. J., Leon, M. B., Smith, C. R., Miller, D. C., Moses, J. W., Tuzcu, E. M., Webb, J. G., Douglas, P. S., Anderson, W. N., Blackstone, E. H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60308-7 · Cited by 1,739
Kapadia, S. R., Leon, M. B., Makkar, R. R., Tuzcu, E. M., Svensson, L. G., Kodali, S., Webb, J. G., Mack, M. J., Douglas, P. S., Thourani, V. H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60290-2 · Cited by 867
Cited by
Basu, S., Berkowitz, S. A., Phillips, R. L., Bitton, A., Landon, B. E., & Phillips, R. S. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.7624 · Cited by 555
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
Guimarães, H. P., Lopes, R. D., de Barros e Silva, P. G. M., Liporace, I. L., Sampaio, R. O., Tarasoutchi, F., Hoffmann-Filho, C. R., de Lemos Soares Patriota, R., Leiria, T. L. L., Lamprea, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2029603 · Cited by 289
Alive and at home: five-year outcomes in older adults following emergency general surgery
Guttman, M. P., Tillmann, B. W., Nathens, A. B., Saskin, R., Bronskill, S. E., Huang, A., & Haas, B. (2021) · Journal of Trauma and Acute Care Surgery · doi:10.1097/ta.0000000000003018 · Cited by 19
Metadata
- Authors
- Kim, D. H., Uno, H., & Wei, L.-J.
- Venue
- JAMA Cardiology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-11-01
- Volume
- 2
- Issue
- 11
- Pages
- 1179
- ISSN
- 2380-6583 (ISSN-L)
- OpenAlex
- W2753244592
- Cited by
- 207
- References
- 2
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results. https://app.cochat.ai/papers/10.1001/jamacardio.2017.2922
- The paper
- Kim, D. H., Uno, H., & Wei, L.-J. (2017). Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results. JAMA Cardiology. https://doi.org/10.1001/jamacardio.2017.2922
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.